+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Pericarditis Drugs Market 2019-2023 - Product Image

Global Pericarditis Drugs Market 2019-2023

  • ID: 4774785
  • Report
  • Region: Global
  • 128 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bayer AG
  • Pfizer Inc.
  • MORE

The global pericarditis drugs market is currently witnessing a high patient pool seeking treatment for the disease. Pericarditis is the most commonly occurring disease of the pericardium. It is the cause for 5% of the total emergency visits to healthcare professionals for chest pain, whereas, in Western Hemisphere, idiopathic pericarditis is the underlying cause for more than 90% cases. Acute pericarditis is diagnosed in 90% cases and is idiopathic in nature, whereas the remaining 10% cases of the total pericarditis diagnosed patients are secondary to bacterial and viral infections, myocardial infarction, autoimmune diseases, uremia, cardiac surgery, trauma, radiation, and any malignancy. Thus, the rising prevalence of pericarditis increases the demand for pericarditis drugs, which drives market growth. Analysts have predicted that the pericarditis drugs market will register a CAGR of over 4% by 2023.

Market Overview

Increasing incidence of recurrent pericardial effusion post cardiac surgery

Recurrent pericardial effusion is the most common complication that occurs after cardiac surgery. Postpericardiotomy syndrome (PPS) is a medical condition that is characterized by the inflammation of the pericardium, which occurs after one to six weeks after surgical incision of the pericardium. Clinically, PPS is characterized by fever, eosinophilia, and pleuritis, and medication treatment involves the use of aspirin and other NSAIDs. In the last few years, colchicine has been evolved as a potent treatment option for recurrent pericardial effusion. The anti-inflammatory effect of colchicine is linked to the ability of the drug to bind with tubulin, resulting in inhibition of neutrophil motility and activity, thereby reducing the inflammation. Colchicine acts by suppressing or inhibiting various leukocytes and fibroblasts at the site of inflammation. Hence, the rising cases of PPS increase the demand for pericarditis drugs, which contributes to market growth.

Side effects associated with pericarditis drugs

The global pericarditis drugs market is predominantly led by NSAIDs and colchicine, owing to their therapeutic benefits. However, they are related to potential side effects. For instance, the US FDA had issued warnings on the use of NSAIDs, stating that they increase the risk of cardiovascular and cerebrovascular events in patients who had a history of coronary artery disease and are being simultaneously receiving NSAIDs. These adverse events are related to the long-term use of these drugs and their escalating dosage. Considering the side effects associated with pericarditis drugs, there is limited use of these drugs in patients with other comorbid cardiovascular diseases, which will hinder the growth prospects of the market during the forecast period.

Competitive Landscape

The market appears to be moderately fragmented. The presence of several companies, including AstraZeneca Plc and Bayer AG makes the competitive environment quite intense. Factors such as the rising prevalence of pericarditis and the increasing incidence of recurrent pericardial effusion post cardiac surgery will provide considerable growth opportunities to the pericarditis drugs manufacturers. Johnson & Johnson Services Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. are some of the major companies covered in this report.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bayer AG
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • NSAIDs - Market size and forecast 2018-2023
  • Colchicine - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • Bayer AG
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits:
Exhibit 01: Global cardiovascular disorder treatment market
Exhibit 02: Segments of global cardiovascular disorder treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Emerging trends in global pericarditis drugs market
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Market overview 2018
Exhibit 10: Analysis of global pericarditis drugs market 2018
Exhibit 11: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 12: Five forces analysis 2018
Exhibit 13: Five forces analysis 2023
Exhibit 14: Bargaining power of buyers
Exhibit 15: Bargaining power of suppliers
Exhibit 16: Threat of new entrants
Exhibit 17: Threat of substitutes
Exhibit 18: Threat of rivalry
Exhibit 19: Market condition - Five forces 2018
Exhibit 20: Product - Market share 2018-2023 (%)
Exhibit 21: Comparison by product
Exhibit 22: NSAIDs - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Treatment regime with NSAIDS for pericarditis
Exhibit 24: NSAIDs - Year-over-year growth 2019-2023 (%)
Exhibit 25: Colchicine - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Colchicine - Year-over-year growth 2019-2023 (%)
Exhibit 27: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Others - Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by product
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Centers for Disease Control and Prevention (CDC) facts about heart disease
Exhibit 35: North America - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in North America
Exhibit 37: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Europe
Exhibit 40: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 41: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 42: Top 3 countries in Asia
Exhibit 43: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 44: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 45: Top 3 countries in ROW
Exhibit 46: Key leading countries
Exhibit 47: Market opportunity
Exhibit 48: Side effects associated with use of NSAIDs
Exhibit 49: Renal impairment associated with use of NSAIDs
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Geriatric population scenario in US 2017
Exhibit 52: Vendor landscape
Exhibit 53: Landscape disruption
Exhibit 54: Vendors covered
Exhibit 55: Vendor classification
Exhibit 56: Market positioning of vendors
Exhibit 57: AstraZeneca Plc - Vendor overview
Exhibit 58: AstraZeneca Plc - Product segments
Exhibit 59: AstraZeneca Plc - Organizational developments
Exhibit 60: AstraZeneca Plc - Geographic focus
Exhibit 61: AstraZeneca Plc - Key offerings
Exhibit 62: AstraZeneca Plc - Key customers
Exhibit 63: Bayer AG - Vendor overview
Exhibit 64: Bayer AG - Product segments
Exhibit 65: Bayer AG - Organizational developments
Exhibit 66: Bayer AG - Geographic focus
Exhibit 67: Bayer AG - Segment focus
Exhibit 68: Bayer AG - Key offerings
Exhibit 69: Bayer AG - Key customers
Exhibit 70: Johnson & Johnson Service, Inc. - Vendor overview
Exhibit 71: Johnson & Johnson Services, Inc. - Business segments
Exhibit 72: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 73: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 74: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 75: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 76: Johnson & Johnson Services, Inc. - Key customers
Exhibit 77: Pfizer Inc. - Vendor overview
Exhibit 78: Pfizer Inc. - Business segments
Exhibit 79: Pfizer Inc. - Organizational developments
Exhibit 80: Pfizer Inc. - Geographic focus
Exhibit 81: Pfizer Inc. - Segment focus
Exhibit 82: Pfizer Inc. - Key offerings
Exhibit 83: Pfizer Inc. - Key customers
Exhibit 84: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 85: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 86: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 87: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 88: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 89: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 90: Validation techniques employed for market sizing
Exhibit 91: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • Bayer AG
  • Pfizer Inc.
  • MORE
The following companies are recognised as the key players in the global pericarditis drugs market: AstraZeneca Plc, Bayer AG, Johnson & Johnson Services Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increased risk of mortality with pericardiectomy.”

According to the report, one of the major drivers in this market is the adoption of dual therapy for pericarditis treatment.

Further, the report states that one of the major factors hindering the growth of this market is the launch of generic pericarditis drugs.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AstraZeneca Plc
  • Bayer AG
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll